Management of Intracerebral Hemorrhage in the Presence of Anticoagulant Therapy

REFERENCES

• Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of anti-thrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449–1457.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro heart survey on atrial fibrillation. Chest. 2010;137:263–272.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (hypertension, abnormal renal/liver function, stroke, leading history or predisposition, labile INR, elderly, drug/ alcohol concomitantly) score. I Am Coll Cardiol. 2011;57:173–180.
   PubMed Web of Science ®Google Scholar
• Lane DA, Lip GYH. Use of the CHA2DS2-VASc and HAS-BLED scores to aid decision-making for thromboprophylaxis in nonvalvular atrial fibrillation. Circulation. 2012;126:860–865.
   PubMed Web of Science ®Google Scholar
• Flaherty ML, Tao H, Haverbusch M, et al. Warfarin use leads to larger intracerebral hematomas. Neurology. 2008;71:1084–1089.
   PubMed Web of Science ®Google Scholar
• Fang M, Chang YC, Hylek EM, et al. Advanced age, anti-coagulation intensity and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Int Med. 2004;141:745–752.
   PubMed Web of Science ®Google Scholar
• Flaherty M, Kissela B, Woo D, et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology. 2007;68:116–121.
   PubMed Web of Science ®Google Scholar
• Huhtakangas J, Tetri S, Juvela S, et al. Effect of increased warfarin use on warfarin-related cerebral hemorrhage: a longitudinal population-based study. Stroke. 2011;42:2431–2435.
   PubMed Web of Science ®Google Scholar
• Banerjee A, Lip GYH. Intracerebral hemorrhage and warfarin. Perceived versus actual risk. Stroke. 2011;42:2383–2384.
   PubMed Web of Science ®Google Scholar
• Delgado Almandoz JE, Yoo AJ, Stone MJ, et al. The spot signs score in primary intracerebral hemorrhage identifies patients at highest risk of in-hospital mortality and poor outcome among survivors. Stroke. 2010;41:54–60.
   PubMed Web of Science ®Google Scholar
• Huynh T, Aviv RI. Contrast extravasation: a surrogate marker of primary intracerebral hemorrhage and secondary expansion. Arch Neurol. 2012;69:278
   PubMed Web of Science ®Google Scholar
• Hemphill JC, Bonovich DC, Besmertis L, et al. The ICH score: a simple, reliable grading scale for intracerebral hemorrhage. Stroke. 2001;30: 891–897.
   Google Scholar
• Zubkov AY, Mandrekar IN, Claassen DO, et al. Predictors of outcome in warfarin-related intracerebral hemorrhage. Arch Neurol. 2008;65:1320–1325.
   PubMed Web of Science ®Google Scholar
• Rost NS, Smith EE, Chang Y, et al. Prediction of functional outcome in patients with primary intracerebral hemorrhage. The FUNC score. Stroke. 2008;39:2304–2309.
   PubMed Web of Science ®Google Scholar
• Anderson CS, Huang Y, Wang JG, et al. Intensive blood pressure reduction in acute cerebral haemorrhagic trial (INTERACT): a randomized pilot trial. Lancet Neurol. 2008;7:391–399.
   PubMed Web of Science ®Google Scholar
• Qureshi Al, Palesch YY, Martin R, et al. Effect of systolic blood pressure reduction on hematoma expansion, perihematoma expansion and three-month outcome among patients with intracerebral hemorrhage. Results from the Antihypertensive Treatment of Acute Cerebral Hemorrhage Study. Arch Neurol. 2010;67:570–576.
   PubMed Web of Science ®Google Scholar
• Morganstern LB, Hemphill JC, Anderson C, et al. Guidelines for management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2010;41:2108–2129.
   PubMed Web of Science ®Google Scholar
• Voetsch B, Kase C. Management of spontaneous intracerebral hemorrhage. In: Biller J, Ferro JM, ed. Evidence-based Management of Stroke. Castle Hill Barnes, UK: Tfm Publishing Ltd; 2011: 175–204.
   Google Scholar
• Flaherty ML. Tao H, Haverbusch M, et al. Warfarin use leads to larger intracerebral hematomas. Neurology. 2008;71:1084–1089.
   PubMed Web of Science ®Google Scholar
• Davis SM, Broderick J, Hennerici M, et al. Hematoma growth is a determinate of mortality and poor outcome after intracerebral hemorrhage. Neurology. 2006;66:1175–1181.
   PubMed Web of Science ®Google Scholar
• Goldstein IN, Thomas SH, Frontiero V, et al. Timing of fresh frozen plasma administration and rapid correction of coagulopathy in warfarin-related intracerebral hemorrhage. Stroke. 2006;37: 151–155.
   PubMed Web of Science ®Google Scholar
• Huttner HB, Schellinger PD, Hartmann M, et al. Hematoma growth in outcome and treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy. Comparison of acute treatment strategies using vitamin K, fresh frozen plasma and prothrombin complex concentrates. Stroke. 2006;37: 1465–1470.
   PubMed Web of Science ®Google Scholar
• Goodnough LT, Shander A. How I treat warfarin-associated coagulopathy in patients with intracerebral hemorrhage. Blood. 2011;117: 6091–6099.
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuunemann HJ; for the American College of Chest Physicians Anti-Thrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: anti-thrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:7S–47S.
   Google Scholar
• Stangier J, Rthgen K, Stahle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate. An open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010;49:259–268.
   PubMed Web of Science ®Google Scholar
• Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM Palareti G. Oral anticoagulant therapy. Anti-thrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141(2 suppl): e445–e885.
   Google Scholar
• Sie P, Samama CM, Godier A, et al. Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis. Arch Cardiovasc Dis. 2011;104: 669–676.
   PubMed Web of Science ®Google Scholar
• van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate-A novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103:1116–1127.
   PubMed Web of Science ®Google Scholar
• Moussouttas M. Challenges and controversies in the medical management of primary and antithrombotic-related intracerebral hemorrhage. Ther Adv Neurol Dis. 2012;5:43–56.
   PubMedGoogle Scholar
• Mendelow AD, Gregson BA, Fernandes HM, et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral hematomas in the International Surgical Trial in Intracerebral Hemorrhage (STITCH): a randomized trial. Lancet. 2005;365:387–397.
   PubMed Web of Science ®Google Scholar
• Ninsky C. Management of supratentorial intracerebral hemorrhage-still a controversy? World Neurosurg. 2012;77:55–56.
   Google Scholar
• Mendelow AD, Gregson BA, Mitchell PM, Murray GD, Rowan EN, Gholkar AR. Surgical trial in lobar intracerebral hemorrhage (STICH II) protocol. Trials. 2011;12:124.
   PubMed Web of Science ®Google Scholar
• Morgan T, Zuccarello M, Narayan R, Keyl P, Lane K, Hanley D. Preliminary findings of the minimally-invasive surgery plus rtPA for intracerebral hemorrhage evacuation (MISTIE) clinical trial. Acta Neurochir Suppl. 2008;105:147–151.
   PubMedGoogle Scholar
• Chen M, Wang Q, Zhu W, et al. Stereotactic aspiration plus subsequent thrombolysis for moderate thalamic hemorrhage. World Neurosurg. 2012;77:122–129.
   PubMedGoogle Scholar
• Sykora M, Steiner T, Poli S, Rocco A, Turcani P, Diedler J. Autonomic effects of intraventricular extension of intracerebral hemorrhage. Neurocrit Care. 2012;16:102–108.
   PubMed Web of Science ®Google Scholar
• LaPointe M, Haines S. Fibrinolytic therapy for intraventricular hemorrhage in adults. Cochrane Database Systematic Rev. 2002; 3:CD003692. doi: 10.1002/14651858.CD003692.
   Google Scholar
• Morgan T, Awad I, Keyl P, Lane K, Hanley D. Preliminary report of the clot lysis evaluating accelerated resolution of intraventricular hemorrhage (CLEAR-IVH) clinical trial. Acta Neurochir Suppl. 2008;105:217–220.
   PubMedGoogle Scholar
• Hinson HE, Hanley DF, Ziai WC. Management of intraventricular hemorrhage. Curr Neurol Neurosci Rep. 2010;10:73–82.
   PubMed Web of Science ®Google Scholar
• Classen DO, Kazemi N, Zubkov AY, Wijdicks EFM, Rabinstein A. Restarting anti-coagulation therapy after warfarin-associated intracerebral hemorrhage. Arch Neurol. 2008;65:1313–1318.
   PubMed Web of Science ®Google Scholar
• Majeed A, Kim Y-K, Roberts R, Holmstrim M, Schulman S. Optimal timing of resumption of warfarin after intracranial hemorrhage. Stroke. 2010;41:2860–2866.
   PubMed Web of Science ®Google Scholar
• Wijdicks EFM. Anticoagulant and antiplatelet therapy in patients with acute or prior intracerebral hemorrhage. In: Basow DS, ed. UpToDate. Waltham, MA; 2012.
   Google Scholar